Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.

por Turner, Christopher D., Gururangan, Sridharan, Eastwood, James, Bottom, Krystal, Watral, Melody, Beason, Rodney, McLendon, Roger E., Friedman, Allan H., Tourt-Uhlig, Sandra, Miller, Langdon L., Friedman, Henry S.
Publicado em 2002

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

por Hoellenriegel, Julia, Meadows, Sarah A., Sivina, Mariela, Wierda, William G., Kantarjian, Hagop, Keating, Michael J., Giese, Neill, O'Brien, Susan, Yu, Albert, Miller, Langdon L., Lannutti, Brian J., Burger, Jan A.
Publicado no Blood (2011)

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

por Vaisitti, Tiziana, Arruga, Francesca, Vitale, Nicoletta, Lee, Thanh-Trang, Ko, Mira, Chadburn, Amy, Braggio, Esteban, Di Napoli, Arianna, Iannello, Andrea, Allan, John N., Miller, Langdon L., Lannutti, Brian J., Furman, Richard R., Jessen, Katti A., Deaglio, Silvia
Publicado no Blood (2021)

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

por O'Brien, Susan M., Lamanna, Nicole, Kipps, Thomas J., Flinn, Ian, Zelenetz, Andrew D., Burger, Jan A., Keating, Michael, Mitra, Siddhartha, Holes, Leanne, Yu, Albert S., Johnson, David M., Miller, Langdon L., Kim, Yeonhee, Dansey, Roger D., Dubowy, Ronald L., Coutre, Steven E.
Publicado no Blood (2015)

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

por Flinn, Ian W., Kahl, Brad S., Leonard, John P., Furman, Richard R., Brown, Jennifer R., Byrd, John C., Wagner-Johnston, Nina D., Coutre, Steve E., Benson, Don M., Peterman, Sissy, Cho, Yoonjin, Webb, Heather K., Johnson, David M., Yu, Albert S., Ulrich, Roger G., Godfrey, Wayne R., Miller, Langdon L., Spurgeon, Stephen E.
Publicado no Blood (2014)

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

por Brown, Jennifer R., Byrd, John C., Coutre, Steven E., Benson, Don M., Flinn, Ian W., Wagner-Johnston, Nina D., Spurgeon, Stephen E., Kahl, Brad S., Bello, Celeste, Webb, Heather K., Johnson, Dave M., Peterman, Sissy, Li, Daniel, Jahn, Thomas M., Lannutti, Brian J., Ulrich, Roger G., Yu, Albert S., Miller, Langdon L., Furman, Richard R.
Publicado em 2014

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

por Gopal, Ajay K., Kahl, Brad S., de Vos, Sven, Wagner-Johnston, Nina D., Schuster, Stephen J., Jurczak, Wojciech J., Flinn, Ian W., Flowers, Christopher R., Martin, Peter, Viardot, Andreas, Blum, Kristie A., Goy, Andre H., Davies, Andrew J., Zinzani, Pier Luigi, Dreyling, Martin, Johnson, Dave, Miller, Langdon L., Holes, Leanne, Li, Daniel, Dansey, Roger D., Godfrey, Wayne R., Salles, Gilles A.
Publicado em 2014

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

por Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D., Hallek, Michael, O’Brien, Susan M.
Publicado em 2014